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Background-—Stent-retriever thrombectomy is the first-line therapy in acute stroke with intracranial large vessel occlusion. In case
of failure of stent-retriever thrombectomy, rescue stent angioplasty might be the only treatment option to achieve permanent
recanalization. This study aims at identifying predictors for poor outcome and complications in a large, multicenter cohort receiving
rescue stent angioplasty.
Methods and Results-—We performed a retrospective analysis of patients with large vessel occlusion who were treated with rescue
stent angioplasty after stent-retriever thrombectomy between 2012 and 2018 in 7 neurovascular centers. We defined 2 binary
outcomes: (1) functional clinical outcome (good modified Rankin Scale, 0–2; and poor modified Rankin Scale, 4–6) and (2) early
symptomatic intracerebral hemorrhage. Impacts of clinical, radiological, and interventional parameters on outcomewere assessed in
uni- andmultivariable logistic regressionmodels. Two hundred ten patients were includedwith target vessels locatedwithin the anterior
circulation (136 of 210; 64.8%) and posterior circulation (74 of 210; 35.2%). Symptomatic intracerebral hemorrhage occured in 22
patients, 86.4% (19 of 22) after anterior and 13.6% (3 of 22) after posterior circulation large vessel occlusion. Good functional outcome
was observed in 44.8% (73 of 163). A higher National Institutes of Health Stroke Scale on admission (adjusted odds ratio, 1.10;
P=0.002), a higher premorbid modified Rankin Scale (adjusted odds ratio, 2.02; P=0.049), and a modified Thrombolysis in Cerebral
Infarction score of 0 to 2a after stenting (adjusted odds ratio, 23.24; P<0.001) were independent predictors of poor functional outcome.
Conclusions-—Use of rescue stent angioplasty can be considered for acute intracranial large vessel occlusion in cases after
unsuccessful stent-retriever thrombectomy. Likelihood of symptomatic intracerebral hemorrhage is higher in anterior circulation
stroke. ( J Am Heart Assoc. 2020;9:e012795. DOI: 10.1161/JAHA.119.012795.)
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S tent-retriever thrombectomy (SRT) is the first-line therapyin acute stroke with intracranial large artery vessel
occlusion (LVO) of the anterior circulation.1–5 The superiority
of SRT compared with best medical treatment has been
proven in several randomized, multicenter trails.6–8 In these
studies, patients treated with SRT achieved high rates of
recanalization with modified Thrombolysis in Cerebral Infarc-
tion (mTICI) grades 2b or 3 up to 88%.9 Despite an initially
successful recanalization, patients may develop immediate
reocclusion of the target vessel. In the majority of these cases,
the underlying pathology is intracranial atherosclerotic dis-
ease,10,11 which is much more prevalent in Asian popula-
tions.11,12
Acute reocclusion or high-grade stenosis after unsuccessful
SRT is associated with poor functional outcome.13 Potential
rescue strategies include angioplasty (PTA), PTA with drug
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eluting balloon,14 and rescue stent angioplasty (RSA)13–16 with
self-expandable stents or balloon-mounted stents.17
The best currently available evidence for endovascular treat-
ment of intracranial atherosclerotic disease is based on the
SAMMPRIS (Stenting and Aggressive Medical Management for
PreventingRecurrent stroke in Intracranial Stenosis) study and the
VISSIT (Vitesse Intracranial Stent Study for Ischemic Stroke
Therapy) study,18,19 showing the superiority of best medical
treatment over elective intracranial stenting. Lately, mostly small
retrospective studies reported consistently on improved func-
tional outcomes after RSA for cases where initial thrombectomy
attempts fail or high-grade stenosis increases the risk for acute
reocclusion.15,20–26 Accordingly, Chang et al reported signifi-
cantly better outcomes after RSA versus medical treatment
representing the largest study (n=50) on RSA.15,27
We analyzed patient data from 7 neurovascular centers to
identify predictors of poor outcome after RSA in the largest
patient-level pooled analysis to date. We hypothesized that we
would be able to identify predictors, both for poor outcome and
hemorrhage, in the postinterventional phase after RSA that
would help in selecting patients and informing future trial design.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study Population
Patients with acute ischemic stroke caused by intracranial LVO
of the anterior and posterior circulation, who received RSA
between February 2012 and October 2018, were identified from
the databases of 7 tertiary stroke centers. The study was
approved by the responsible ethics committee (Aerztekammer
Nordrhein, Duesseldorf, Germany), and therefore no informed
consent from every individual could be waived. As inclusion
criteria, we defined (1) evidence of intracranial large vessel
occlusion, (2) absence of intracranial hemorrhage, and (3) acute
reocclusion or persistent high-grade stenosis after SRT. Patients
with missing recanalization at any time during the procedure
were excluded. Differentiation between high-grade stenosis,
residual clot, or dissection as the cause for high-grade stenosis or
reocclusion was not made. Patients with extra-/intracranial
tandem lesions were excluded.
All anonymized patient data were entered in the databases
of the participating centers. Data from 41 of 210 patients
have been published already.13,23
Baseline Characteristics
Patient data were evaluated regarding demographics, premorbid
disability (modified Rankin Scale [mRS] score), and stroke
severity on admission using the National Institute of Health
Stroke Scale (NIHSS). NIHSS scoring was performed exclusively
by experienced neurologists, both on admission and on the
following days on the stroke unit.
Administration of intravenous recombinant tissue plas-
minogen activator was recorded. If available, time intervals
between onset and imaging time to groin puncture, as well as
procedural data, such as final endovascular revascularization,
were documented.
Intracranial anterior circulation LVO was defined as
occlusion of: (1) internal carotid artery (carotid T), (2) anterior
cerebral artery, (3) the first segment of the middle cerebral
artery (M1), and (4) the second segment of the middle
cerebral artery (M2). Intracranial posterior circulation LVO
was defined as occlusion of the: (1) basilar artery and (2)
intracranial segment of the vertebral arteries.
Interventional and Postprocedural Parameters
Interventional data, including type of stent-retriever, number
of thrombectomy maneuvers, as well as the stent design
(balloon or self-expanding), were evaluated. The recanalization
result was graded by the mTICI (modified Thrombolysis in
Cerebral Infarction) score.28 Time to first PTA of the
intracranial target vessel as well as the antiplatelet regimes
were recorded.
Complications, including the occurrence of symptomatic
intracranial hemorrhage (sICH) resulting in a deterioration of
≥4 NIHSS points and postinterventional stent occlusion and
restenosis, were recorded. NIHSS score on admission and at
discharge from the hospital as well as the mRS after 90 days
were documented. A final mRS score of 0 to 2 was defined as
“good functional clinical outcome.”
Endovascular Revascularization
Endovascular treatment was performed as a state-of-the art
stent-retriever–based procedure using common guiding and
Clinical Perspective
What Is New?
• In case of unsuccessful recanalization of intracranial vessels
in acute stroke, rescue stenting using self-expandable
stents can achieve permanent recanalization.
What Are the Clinical Implications?
• Rate of good functional clinical outcome is high, and rate of
symptomatic intracerebral hemorrhage is acceptable; there-
fore, rescue stenting should be considered rather than
leaving the patient with a nonrecanalized vessel.
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balloon guiding catheters. Numbers of retrieval maneuvers as
well as the PTA and intracranial stenting after unsuccessful
thrombectomy were left to the interventionalist’s decision.
Statistical Analysis
Univariable distribution of metric variables is described by
median and interquartile range (IQR). For categorical data,
absolute and relative frequencies are given. The Mann–Whitney
U test orv2 test was used to compare 2 independent samples on
a metric or categorical outcome, respectively. We defined 2
binary outcomes: (1) sICH occurrence in the immediate postin-
terventional phase (yes/no) and (2) functional clinical outcome
(good [mRS 0–2] and poor [mRS 4–6]). Impacts of clinical,
radiological, and interventional parameters on outcome were
assessed in uni- and multivariable logistic regression models.
Multivariablemodel building was performed using a step-wise
variable selection procedure: In a first step, all factors were fitted
together by a step-wise forward selection (inclusion: P value of
the score test ≤0.05 and exclusion: P value of the likelihood ratio
test >0.1). Then, the factors of the model from step 1 were fitted
together with all pair-wise interactions in a second block using
step-wise forward selection (inclusion: P value of the score test
≤0.05 and exclusion: P value of the likelihood ratio test >0.1).
Given for selected variables are odds ratios (ORs)with95%CI and
P value of a likelihood ratio test. For nonselected variables, the P
value of score test is displayed. Odds were calculated as ratio of
the probability for poor outcome to the probability of good
outcome. Because of partially missing data of Alberta Stroke
Program Early CT Score at the end of the procedure, these
variables were not included into logistic regression models. No
adjustment for multiple testing was performed, and analyses are
regarded as explorative. Local, unadjusted P<0.05 was consid-
ered as statistically noticeable.
Statistical analyses were performed in SPSS (version 24;
IBM Corporation, Armonk, NY) and in SAS software (version
9.4; SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics
A total of 210 patients fulfilled the inclusion criteria and were
included for further analysis. The total amount of thrombec-
tomies performed in the participating centers in this time
period was 4751, resulting in a percentage for RSA of 4.4%.
In the stenting group, median age of patients was 67 years
(IQR, 59–75), and 84 (40%) patients were female. Median
NIHSS score on admission was 13 (IQR, 3–14) and the
premorbid mRS 0 (IQR 0–1). Detailed baseline characteristics
are listed in Table 1. The M1 segment of the middle cerebral
artery was occluded in 85 patients (40.5%) and the basilar
artery in 46 (21.9%). Median time between computed
tomography to groin puncture was 99 minutes (IQR, 60–
137). Intravenous recombinant tissue plasminogen activator
was administered in 66 of 210 patients (31.4%) before the
recanalization procedure.
Interventional Data
In 201 of 210 patients (95.7%), a self-expanding stent was
implanted and in 9 (4.3%) a balloon-expanding stent. The most
commonly used clot-retrieving device was the Solitaire FR
Stent (80 of 210 patients [40%]). The numbers of SRT
maneuvers before stenting ranged from 1 to 17, with a
median of 2 (IQR, 1–3). The final run after PTA/stenting
confirmed a successful recanalization (mTICI 2b/3) in 174
(82.9%); thereof, a successful recanalization was observed in
106 (77.9%) of the anterior circulation LVO and in 68 (97.1%)
of the posterior circulation LVO.
For RSA, the Acclino/Acclino flex/Credo stent (Acandis
GmbH, Pforzheim, Germany) was placed in 61 of 201 (29%),
the Solitaire AB Stent (ev3/Medtronic, Irvine, CA) in 45 of 201
(31%) patients, the Wingspan Stent (Stryker) in 8 of 201
(3.8%), the Neuroform (Stryker) in 65 of 201 patients (20.0%),
and others (eg Leo Stent [Balt, Montmorency, France],
Coroflex Blue Ultra Stent [B. Braun, Berlin, Germany], the
Enterprise Stent [Codman Neuro, Raynham, MA], and Pharos
Stent [Codman]) in 31 of 201 patients (14.8%).
There was not a standard protocol for antiplatelet therapy
regime. All patients received at least monoantiaggregation or
a GpIIb/IIIa antagonist in the acute setting. Detailed data for
antiaggregation were available in 150 patients. In this group,
124 patients (82%) received a GpIIb/IIIa antagonist, mainly
eptifibatide (109 cases), Tirofiban (12 cases), and Abxicimab
(3 cases). GpIIb/IIIa antagonists were continued until the
control computed tomography scan 24 hours after the
procedure. After that, mono- or double antiaggregation was
continued depending on each center’s decision.
Symptomatic Intracerebral Hemorrhage
Of the 210 patients, 22 (10.5%) experienced an sICH in the
immediate postinterventional phase. Median age differed
statistically noticeablely between patients with sICH (median,
74 [IQR, 65–88]) and no sICH (median, 66 [IQR 58–74];
P<0.004). Nineteen of 22 patients with sICH (86.4%) were
treated for anterior circulation LVO whereas there were 3
patients with posterior circulation LVO (P<0.025; Table 1). A
successful recanalization after RSA (mTICI 2b-3) was signifi-
cantly more often observed in patients without sICH compared
with patients with sICH (all P=0.004; Table 1). Logistic
regression analysis was performed to assess the association
between various clinical and interventional parameters and
sICH in the postinterventional phase.
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In univariable logistic regression, higher age (P=0.007),
female sex (P=0.021), and anterior circulation LVO (P=0.035)
and an unsuccessful recanalization (mTICI of 0–2a) after RSA
(P=0.007) were associated with presence of sICH after acute
stenting (Table 2). Multivariable logistic regression analysis
confirmed an unsuccessful recanalization (mTICI of 0–2a)
after RSA as an independent predictor of sICH (adjusted OR,
4.16; P=0.007; e-value=3.49629; Table 3). Intravenous
thrombolysis, premorbid mRS, NIHSS on admission, and
number of SRT attempts were not independent predictors of
sICH in the logistic regression analysis.
Functional Clinical Outcome After Acute
Intracranial Stenting in Stroke Patients
Functional clinical outcome (mRS) after 90 days was only
available in 163 of the patients (median, 3 [IQR, 1–5]).
Table 1. Comparison of Baseline Demographic, Clinical, and Radiological Characteristics Between Patients With sICH and Without
Intracranial Hemorrhage After Acute Stenting
Baseline Characteristics All (n=210) Without sICH (n=188) With sICH (n=22) P Value
Age (y), median (IQR) 67 (59; 75) 66 (58; 74) 74 (65; 88) 0.004
Female, n (%) 84 (40.0) 70 (37.2) 14 (63.6) 0.017
CT parameters, median (IQR)
ASPECTS 9 (8; 10) 9 (8; 10) 8 (7; 9) 0.209
Clinical parameters, median (IQR)
NIHSS on admission 13 (8;18) 12 (7; 18) 14 (12; 21) 0.032
Premorbid mRS 0 (0;1) 0 (0; 1) 0 (0; 2) 0.249
NIHSS at discharge 6 (3;14) 5 (2; 12) 20 (11; 32) <0.001
mRS, 90 days 3 (1; 5) 2 (1; 5) 6 (5; 6) <0.001
Occlusion type, n (%) 0.186
ICA 41 (19.5) 35 (18.6) 6 (27.3)
ACA 1 (0.5) 1 (0.5) 0 (0)
M1 85 (40.5) 73 (38.8) 12 (54.5)
M2 8 (3.8) 7 (3.7) 1 (4.5)
VA 29 (13.8) 26 (13.8) 3 (13.6)
BA 46 (21.9) 46 (24.5) 0 (0)
Anterior circulation (vs posterior circulation) 136 (64.8) 117 (62.2) 19 (86.4) 0.025
Procedure process and results
Intravenous thrombolysis, n (%) 66 (31.4) 57 (30.3) 9 (40.9) 0.311
CT to groin puncture (min), median (IQR) 99 (60.0; 137.0) 98 (60.0; 135.8) 106.5 (75.3; 146.8) 0.629
Passes of retriever 2 (1;3) 2 (1;3) 2 (1;4) 0.829
mTICI after last stent-retriever/aspiration (TICI 2b/3), n (%) 68 (32.4) 65 (34.6) 3 (13.6) 0.285
mTICI in final run after RSA (TICI 2b/3), n (%) 174 (82.9) 160 (85.1) 14 (63.6) 0.004
Stent category, n (%)
Self-expandable stents 201 (95.7) 179 (89.1) 22 (10.9)
Balloon-expandable stents 9 (4.3) 9 (4.8) 0 (0)
Stent type, n (%)
Acclino flex 61 (29.0) 59 (31.4) 2 (9.1)
Solitaire 45 (31.0) 37 (19.7) 8 (36.4)
Neuroform 65 (29.0) 56 (29.8) 9 (40.9)
Wingspan 8 (3.8) 7 (3.7) 1 (4.5)
Others (Leo, Enterprise, coroflex, Pharos) 31 (14.8) 29 (15.4) 2 (19.4)
ACA indicates anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; BA, basilar artery; CT, computed tomography; ICA, internal carotid artery; INR, international
normalized ratio; IQR, interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; RSA, rescue
stent angioplasty; sICH, symptomatic intracranial hemorrhage, hemorrhagic transformation; TICI, thrombolysis in cerebral infarction; VA, vertebral artery.
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Seventy-three of 163 (44.8%) patients had a good functional
clinical outcome (mRS 0–2) after 3 months. In-house mortal-
ity was 25 of 210 (11.9%); overall mortality after 3 months
was 39 of 210 (18.5%). A higher NIHSS on admission,
premorbid mRS, and NIHSS at discharge were significantly
more often observed in patients with a poor outcome
compared with patients with a good outcome (all P<0.001;
Table 4). The number of retrieval maneuvers as an indirect
parameter for procedure duration and complexity differed
noticeably between patients with good (median, 2 [IQR, 1–3])
and poor functional outcome (median, 3 [IQR, 1–4]; P<0.035).
A successful recanalization after RSA (mTICI 2b–3) was
significantly more often observed in patients with good
outcome compared with patients with poor outcome
(P<0.001; Table 4).
In univariable logistic regression, higher age (P=0.002),
higher NIHSS on admission (P=0.001), higher premorbid mRS
(P=0.001), higher number of retrievals (P=0.029), and an
unsuccessful recanalization (mTICI of 0–2a) after RSA
(P<0.001) were associated with a poor functional outcome
in the postinterventional phase after acute stenting (Table 5).
Multivariable logistic regression analysis identified higher
NIHSS at admission (adjusted OR, 1.10; P=0.002; e-
value=1.275), higher premorbid mRS (adjusted OR, 2.02;
P=0.002; e-value=2.195), and an unsuccessful recanalization
(mTICI of 0–2a) after RSA (adjusted OR, 23.24; P<0.00; e-
value=9.113) as independent predictors of poor functional
outcome after acute stenting (Table 6).
Discussion
This analysis of data from 7 centers worldwide is the largest
published series for acute RSA so far, allowing, for the first
time, the identification of predictive factors for functional
clinical outcome. The study population was broad and
representative of daily clinical practice, including patients
with anterior and posterior circulation, low NIHSS, and long
duration from symptom onset to presentation at the hospital.
In our study, good outcome was observed in 73 of 163
(44.8%) patients with recorded outcomes at 90 days. Even if
all patients without recorded outcomes were defined as poor
outcome, the rate of good outcome would still be 35%. This is
considerably better than the rates of 7% to 22% in cohorts
with reocclusion or persistent occlusion reports without
RSA.15,22,23,30 The rate of good functional clinical outcome
in our analysis is also substantially better than in patients
without recanalization (Thrombolysis in Cerebral Infarction 0/
1) in the meta-analysis of the large thrombectomy randomized
controlled trials.31 These results are comparable with the data
of a recent meta-analysis32 of 160 patients treated with RSA,
which showed 43% good functional outcome.
Placement of an intracranial stent requires antiplatelet
therapy, which might increase the risk of intracranial bleeding
in acute stroke. The rate of sICH in our analysis (11%) was
somewhat higher than in the aggregated thrombectomy
studies without intracranial stenting of 4.4%,7 but comparable
with the 12% in the meta-analysis of Wareham et al.32 In the
MR CLEAN1 (Multicenter Randomized Clinical Trial of
Endovascular Treatment for Acute Ischemic Stroke in the
Netherlands) trial, the rate of sICH was 7.7% in the
interventional group. Behme et al33 reported a hemorrhage
rate of 9% in emergency stenting of the internal carotid artery
in tandem lesions, where an antiplatelet therapy was also
administered.
A standard of antiplatelet therapy for acute intracranial
stenting does not exist.34 In our study, GpIIb/IIIa antagonists
were used in most of the cases. The minority of cases were
Table 2. Univariable Analysis of Predictors of sICH in the
Immediate Postinterventional Phase After Acute Stenting
OR 95% CI P Value
Age, y 1.06 0.02–1.10 0.007
Sex (ref: male) 0.34 0.35–0.85 0.021
NIHSS on admission 1.05 0.99–1.11 0.090




Intravenous thrombolysis (ref: no) 0.63 0.25–1.55 0.315
Passes of retriever 1.06 0.89–1.27 0.488
mTICI in final run after RSA 3.81 1.45–10.04 0.007
Given for selected variables are odds ratios (OR) with 95% CI and P value of likelihood
ratio test. mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; NIHSS, National Institutes of Health Stroke Scale; RSA, rescue stent
angioplasty; sICH, symptomatic intracranial hemorrhage, hemorrhagic transformation.
Table 3. Multivariable Analysis of Predictors of sICH in the
Immediate Postinterventional Phase After Acute Stenting
OR 95% CI P Value
Age, y 1.06 1.02–1.11 0.008
Sex (ref: male) 2.11 0.73–6.12 NS: 0.071
NIHSS on admission 1.04 0.96–1.12 NS: 0.288
Premorbid mRS 1.44 0.90–2.31 NS: 227
Target vessel
(ref: posterior circulation)
3.31 0.66–16.58 NS: 0.71
Intravenous thrombolysis 1.55 0.53–4.56 NS: 0.482
Passes of retriever 1.00 0.79–1.26 NS: 0.662
mTICI in final run after RSA 4.16 1.49–11.06 0.007
Given for selected variables are odds ratios (OR) with 95% CI and P value of likelihood
ratio test. mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; NIHSS, National Institutes of Health Stroke Scale; RSA, rescue stent
angioplasty; sICH, symptomatic intracranial hemorrhage, hemorrhagic transformation.
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treated with antiplatelet drugs acetylsalicylic acid, dipyri-
damol, or clopidogrel as sole or combined therapy. For
intracranial stenting, the decision for double antiplatelet
therapy or GpIIb/IIIa antagonist administration is based on
experience with acute stenting not only in stenosis treatment,
but also on aneurysm treatment, including implantation of
braided stents and flow diverters. For the acute stroke setting,
it is unclear which antiplatelet therapy offers the best balance
between bleeding and stent occlusion risk. A main finding of
this study is the significant difference in hemorrhage rate
between anterior (N=19; 11%) and posterior circulation (N=3;
4.1%).
We did not observe any technical complications explaining
the higher rate of sICH in the anterior circulation. Data in the
literature for sICH in posterior circulation stroke thrombec-
tomy without stenting vary between 4% and 9%.35,36 There are
no larger series of posterior circulation RSA to compare with
our study.
Table 4. Comparison of Baseline Demographic, Clinical, and Radiological Characteristics Between Patients With Good (mRS 1–2)





(mRS 3–6; n=90) P Value
Age (y), median (IQR) 63 (54; 72) 69 (62; 77) 0.001
Female, n (%) 28 (38.4) 39 (43.3) 0.521
CT parameters, median (IQR)
ASPECTS 9 (8; 10) 8 (7; 9) 0.072
Clinical parameters, median (IQR)
NIHSS on admission 11 (6; 16) 15 (11; 20) <0.001
Premorbid mRS 0 (0; 0) 0 (0; 2) <0.001
NIHSS at discharge 2 (0; 5) 14 (10; 23) <0.001
Occlusion type, n (%) 0.314
ICA 17 (23.3) 16 (17.8)
M1 29 (39.7) 39 (43.3)
M2 1 (1.4) 4 (4.4)
VA 7 (9.6) 15 (16.7)
BA 19 (26.0) 16 (17.8)
Anterior circulation (vs posterior circulation) 47 (64.4) 60 (66.7) 0.760
Procedure process and results
Intravenous thrombolysis, n (%) 26 (35.6) 29 (32.2) 0.649
CT-to-groin puncture (min), median (IQR) 103 (66.3; 166.0) 92.5 (53.0; 132.5) 0.273
Passes of retriever 2 (1;3) 3 (1;4) 0.035
mTICI after last stent-retriever/aspiration (TICI 2b/3), n (%), 63 missings 26 (35.6) 19 (21.1) 0.119
mTICI in final run after RSA, n (%) 70 (95.9) 63 (70.0) <0.001
Stent category, n (%)
Self-expandable stents 68 (93.2) 88 (97.8) 0.147
Balloon-expandable stents 5 (6.8) 2 (2.2)
Stent type, n (%)
Acclino flex 15 (20.5) 20 (22.2)
Solitaire 15 (20.5) 12 (13.3)
Neuroform 21 (28.8) 27 (30.0)
Wingspan 2 (2.7) 6 (6.7)
Others (Leo, Enterprise, coroflex, Pharos) 15 (20.5) 12 (13.3)
ASPECTS indicates Alberta Stroke Program Early CT Score; BA, basilar artery; CT, computed tomography; ICA, internal carotid artery; IQR, interquartile range; mRS, modified Rankin Scale;
mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; RSA, rescue stent angioplasty; TICI, thrombolysis in cerebral infarction; VA, vertebral
artery.
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A possible consequence of our finding could be that
postinterventional management, and especially management
of blood pressure, should be paid even more attention in
anterior circulation stroke.
There was also a predominance of sICH in female patients,
which did not reach significance in the multivariate analysis.
Intravenous thrombolysis with PTA had no influence on the
bleeding rate. Therefore, the decision for a stent should not be
influenced by the administration of intravenous tissue plas-
minogen activator.
The more retriever passes performed, the worse the
outcome. The number of retriever maneuvers reflects the
overall procedure time and complexity. This might indicate
that in cases of unsuccessful thrombectomy, the decision
toward stenting should not be made too late. On the other
hand, not every sticky clot should be stented, given that we
have to consider the significant hemorrhage risk, especially in
the anterior circulation. Recent research suggests that
recanalization improves clinical outcome only if achieved with
not more than 3 attempts.22,37,38
Concerning the interventional method used, there was 1
statistically significant finding. Theuseof theAcclino/Acclinoflex
stent (Acandis GmbH) was associated with a significantly lower
rate of sICH (3.3% versus 14.3%; P<0.01). This stent is a new-
generation self-expanding stent, which requires no exchange
maneuver and can be delivered through a standard 0.017
microcatheter or theNeuroSpeed balloon directly. These features
of easier delivery might increase the safety of the procedure.
Moreover, other factors, from stent design such as the radial
force, metal surface, and release mechanism, might play a role
here. On the other hand, the stent has been available since 2014,
and therefore the learning curve of the endovascular sites might
be more advanced. However, the included sites were all very
experienced in neurointerventions and acute stroke therapy.
Higher age, low Alberta Stroke Program Early CT Score,
high NIHSS, and higher premorbid mRS were predictors for a
poor outcome. These findings correlate with findings in other
stroke treatment studies. Also, imaging to groin time plays a
significant role for the outcome, as proven in other thrombec-
tomy trials. From other studies, it is known that a longer
procedural time decreases the chance for a good outcome.
Limitations
In our retrospective, multicenter analysis, a high number of
data are missing such as Alberta Stroke Program Early CT
Score and mRS outcome data of 47 patients at 90-days’
follow-up. This drawback is attributable to the retrospective
nature of our study. Several centers anonymized their results,
and analyzing these variables to complete a full data set was
not possible. We presumed a poor outcome for the 46
patients with missing follow-up mRS data. This might be too
pessimistic given that of the 46 patients lost for 90-days’ mRS
follow-up (32%), 18 had had an NIHSS score at discharge of
≤4 points. It is unlikely that all of these patients had a poor
neurological outcome.
The criteria for stenting were up to the interventionalist’s
decision, which could have caused a selection bias.
The antiplatelet regime in this study was not homogenous
and partially unknown. Thus, we cannot conclude whether the
preferred administration of GpIIb/IIIa antagonists is superior
to other antiplatelet drugs (acetylsalicylic acid, dipyridamole,
and clopidogrel) or newer, fast deliverable drugs like
Ticagrelor. However, despite these limitations, we believe
Table 6. Multivariate Analysis of Predictors of Poor Clinical
Outcome (mRS 3–6 at 90 Days) After Acute Stenting (n=151)*
OR 95% CI P Value
Age, y 1.04 1.00–1.06 0.016
Sex (ref: male) 0.79 0.34–1.84 NS: 0.661
NIHSS on admission 1.10 1.03–1.16 0.002
Premorbid mRS 2.02 1.32–3.36 0.002
Target vessel (ref:
posterior circulation)
0.59 0.23–1.49 NS: 0.375
Intravenous thrombolysis 0.54 0.22–1.32 NS: 0.199
Passes of retriever 1.23 0.96–1.67 NS: 0.269
mTICI in final run after RSA 23.24 4.65–116.06 <0.001
Given for selected variables are odds ratios (OR) with 95% CI and P value of likelihood
ratio test. mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; NIHSS, National Institutes of Health Stroke Scale; NS, not significant; RSA,
rescue stent angioplasty;
*Forty-seven missing mRS values.
Table 5. Univariable Analysis of Predictors of Poor Clinical
Outcome (mRS 3–6 at 90 Days) After Acute Stenting (n=151)*
OR 95% CI P Value
Age, y 1.04 1.02–1.07 0.002
Sex (ref: male) 1.22 0.65–2.30 0.521
NIHSS on admission 1.08 1.04–1.14 0.001




Intravenous thrombolysis 1.16 0.61–2.23 0.649
Passes of retriever 1.22 1.02–1.46 0.029
mTICI in final run after RSA 15.0 3.42–65.64 <0.001
Given for selected variables are odds ratios (OR) with 95% CI and P value of likelihood
ratio test. mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral
Infarction; NIHSS, National Institutes of Health Stroke Scale; RSA, rescue stent
angioplasty.
*Forty-seven missing mRS values.
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that this analysis allows us to draw valid and novel
conclusions.
Conclusions
The rate of good outcome after intracranial rescue stenting
after mechanical thrombectomy failure is considerably higher
than reported for patients with persistent occlusions and
comparable with that of patients treated with thrombectomy
alone. A main predictor for good outcome was a low number
of thrombectomy maneuvers before stenting. The observed
hemorrhage rate is higher than that in regular thrombectomy
procedures, but seems acceptable. Hemorrhage is more likely
in the anterior circulation. Acute intracranial rescue stenting
is a valid treatment option that deserves further study in
prospective trials.
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